scholarly journals Effect of Mazindol on Body Weight and Insulin Sensitivity in Severely Obese Patients after a Very-Low-Calorie Diet Therapy.

1996 ◽  
Vol 43 (6) ◽  
pp. 671-677 ◽  
Author(s):  
TETSUO NISHIKAWA ◽  
TAKASHI IIZUKA ◽  
MASAO OMURA ◽  
NOBUHIKO KURAMOTO ◽  
TAKASHI MIKI ◽  
...  
Keyword(s):  
Body Weight ◽  
Insulin Sensitivity ◽  
Diet Therapy ◽  
Obese Patients ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Severely Obese

scholarly journals Effects of a 3-Week Hospital-Controlled Very-Low-Calorie Diet in Severely Obese Patients

Nutrients ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 4468
Author(s):  
Ivan Ožvald ◽  
Dragan Božičević ◽  
Lidija Duh ◽  
Ivana Vinković Vrček ◽  
Ivan Pavičić ◽  
...  
Keyword(s):  
Dna Damage ◽  
Weight Loss ◽  
Health Improvement ◽  
Healthy Population ◽  
Obese Patients ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Severely Obese

Although a very-low-calorie diet (VLCD) is considered safe and has demonstrated benefits among other types of diets, data are scarce concerning its effects on improving health and weight loss in severely obese patients. As part of the personalized weight loss program developed at the Duga Resa Special Hospital for Extended Treatment, Croatia, we evaluated anthropometric, biochemical, and permanent DNA damage parameters (assessed with the cytochalasin B-blocked micronucleus cytome assay—CBMN) in severely obese patients (BMI ≥ 35 kg m−2) after 3-weeks on a 567 kcal, hospital-controlled VLCD. This is the first study on the permanent genomic (in)stability in such VLCD patients. VLCDs caused significant decreases in weight (loss), parameters of the lipid profile, urea, insulin resistance, and reduced glutathione (GSH). Genomic instability parameters were lowered by half, reaching reference values usually found in the healthy population. A correlation was found between GSH decrease and reduced DNA damage. VLCDs revealed susceptible individuals with remaining higher DNA damage for further monitoring. In a highly heterogeneous group (class II and III in obesity, differences in weight, BMI, and other categories) consisting of 26 obese patients, the approach demonstrated its usefulness and benefits in health improvement, enabling an individual approach to further monitoring, diagnosis, treatment, and risk assessment based on changing anthropometric/biochemical VLCD parameters, and CBMN results.

Clinical Impact of a 6-Week Preoperative Very Low Calorie Diet on Body Weight and Liver Size in Morbidly Obese Patients

2013 ◽  
Vol 23 (10) ◽  
pp. 1624-1631 ◽  
Author(s):  
Jordán González-Pérez ◽  
Sofía Sánchez-Leenheer ◽  
Alfredo Rivas Delgado ◽  
Lizbeth González-Vargas ◽  
Mariana Díaz-Zamudio ◽  
...  
Keyword(s):  
Body Weight ◽  
Clinical Impact ◽  
Morbidly Obese ◽  
Obese Patients ◽  
Very Low Calorie Diet ◽  
Liver Size ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet

PP211-MON VERY LOW CALORIE DIET COULD CHANGE IMMUNE STATUS IN SEVERELY OBESE PATIENTS

2012 ◽  
Vol 7 (1) ◽  
pp. 221-222
Author(s):  
M.D. Ballesteros-Pomar ◽  
A. Calleja-Fernández ◽  
S. Calleja-Antolín ◽  
R. Diez-Rodríguez ◽  
A. Vidal-Casariego ◽  
...  
Keyword(s):  
Immune Status ◽  
Obese Patients ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Severely Obese

Body Weight Loss by Very-Low-Calorie Diet Program Improves Small Artery Reactive Hyperemia in Severely Obese Patients

2012 ◽  
Vol 23 (1) ◽  
pp. 17-23 ◽  
Author(s):  
J. Merino ◽  
I. Megias-Rangil ◽  
R. Ferré ◽  
N. Plana ◽  
J. Girona ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Reactive Hyperemia ◽  
Body Weight Loss ◽  
Obese Patients ◽  
Small Artery ◽  
Very Low Calorie Diet ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Severely Obese

Metabolic Consequences of Very-Low-Calorie Diet Therapy in Obese Non-insulin-dependent Diabetic and Nondiabetic Subjects

Diabetes ◽  
1986 ◽  
Vol 35 (2) ◽  
pp. 155-164 ◽  
Author(s):  
R. R. Henry ◽  
T. A. Wiest-Kent ◽  
L. Scheaffer ◽  
O. G. Kolterman ◽  
J. M. Olefsky
Keyword(s):  
Diet Therapy ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Insulin Dependent ◽  
Insulin Dependent Diabetic

The effects of very low calorie diet and exercise on insulin sensitivity and secretion in obese type 2 diabetics

2000 ◽  
Vol 50 ◽  
pp. 342
Author(s):  
Munehide Matsuhisa ◽  
Shinichi Gorogawa ◽  
Kentaro Ohtoshi ◽  
Rieko Hayaishi ◽  
Tetsuyuki Yasuda ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Type 2 Diabetics ◽  
Diet And Exercise ◽  
Calorie Diet

scholarly journals Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e031431
Author(s):  
Simon Birk Kjær Jensen ◽  
Julie Rehné Lundgren ◽  
Charlotte Janus ◽  
Christian Rimer Juhl ◽  
Lisa Møller Olsen ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Receptor Agonist ◽  
Controlled Trial ◽  
Good Clinical Practice ◽  
Study Groups ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet

IntroductionThe success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a glucagon-like peptide-1 receptor agonist (liraglutide), physical exercise or the combination of both treatments as compared with placebo in individuals with obesity.Methods and analysisThis is an investigator-initiated, randomised, placebo-controlled, parallel group trial. We will enrol expectedly 200 women and men (age 18–65 years) with obesity (body mass index 32–43 kg/m2) to adhere to a very low-calorie diet (800 kcal/day) for 8 weeks in order to lose at least 5% of body weight. Subsequently, participants will be randomised in a 1:1:1:1 ratio to one of four study groups for 52 weeks: (1) placebo, (2) exercise 150 min/week+placebo, (3) liraglutide 3.0 mg/day and (4) exercise 150 min/week+liraglutide 3.0 mg/day. The primary endpoint is change in body weight from randomisation to end-of-treatment.Ethics and disseminationThe trial has been approved by the ethical committee of the Capital Region of Denmark and the Danish Medicines Agency. The trial will be conducted in agreement with the Declaration of Helsinki and monitored to follow the guidelines for good clinical practice. Results will be submitted for publication in international peer-reviewed scientific journals.Trial registration number2015-005585-32

Sign in / Sign up

Export Citation Format

Share Document